Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Jun 13, 2023 9:12pm
172 Views
Post# 35494996

RE:Rebranding the Sort1

RE:Rebranding the Sort1I thought the presentation today was encouraging and I came away feeling cautiously optimistic after  the many head fakes we have been through, felling like we have a good shot at POC and a potential blockbuster platform, however, We desperately need $$ so what’s the point of this presentation if Thera won’t make the effort to get it in the right ears?

scarlet1967 wrote: After the sudden pause the program lost its credibility, many and I believe the majority of them (retail investors) felt burned sold and moved on. It will be an uphill struggle to get those folks back after many lost their hard earned money on their investment but as we know they didn't have a great deal of exposure from the start so now the job is to get more demand targeting as many investors as possible. The name change of the PDC is a starter and today they made a good effort to explain the logics behind the amended protocol. The perception of the protocol is failure and the ascribed value is negative. I read elsewhere the costs are over $20 million which is incorrect, folks talking about a study with good pre clinical but not working in the clinic which is not necessarily true. The company needs to make efforts explaining many things among others costs, timing, odds of success and financial rewards which is not zero as many believe. Sell it as an improvement of previous prtocol based on facts in hands with better probability of success and sell it to folks who have not been targeted, build a new base of believers. It's a restart so it should be branded as a restart. They have to deal with the scepticism of the program and sell it as a brand new protocol. I believe only then they can expect rejuvenated interest from investors. It's hard sell but absolutely necessary otherwise only good or great results will do the trick. No value/expectation and possibly negative value is included in the SP for an phase 1 clinical trial with potential good even great prospects which is not any shareholder friendly company with valuation at one times sales should ignore. So start the hard sell and keep it going. Try different ways reaching/ adding to Your audience.


<< Previous
Bullboard Posts
Next >>